Nirsevimab

• Description :

  Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV) . Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections[1][2].

• Product Name Alternative :

  MEDI8897

• UNSPSC :

  12352203

• Target :

  RSV

• Type :

  Inhibitory Antibodies

• Related Pathways :

  Anti-infection

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Infection

• Assay Protocol :

  https://www.medchemexpress.com/nirsevimab.html

• Purity :

  98.00

• Solubility :

  10 mM in DMSO

• Smiles :

  [Nirsevimab]

• Molecular Weight :

  (146.31 kDa)

• References & Citations :

  [1]Brady T, et al. Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection. Front Immunol. 2023 Oct 11;14:1283120.|[2]Ma J, et. Exacerbated lung inflammation in offspring with high maternal antibody levels following secondary RSV exposure. Front Immunol. 2024 Apr 30;15:1377374.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  Store at -80°C for 2 years

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Launched

• CAS Number :

  [1989556-22-0]